on Amund Eriksen is co-founder and co-inventor of the Targovax technology. He has more than 30 years of experience in the pharmaceutical and biotech industry (Nycomed, Norsk Hydro, GemVax, Pharmexa and Lytix Biopharma). Mr Eriksen has previously held several senior positions as scientist, project leader and manager within development of cancer immunotherapy from discovery and early preclinical to phase III clinical development. He is co-inventor of several patents for peptide cancer immune activators. Mr Eriksen holds a MSc in Chemistry from the University of Oslo. He is a Norwegian citizen, and resides in Norway.